Mark Zuckerberg and Priscilla Chan have made BioHub their primary philanthropic…

BioHub is positioning itself as an open‑science engine that couples frontier AI with frontier biology to build hierarchical world models of living systems. In this episode Mark Zuckerberg, Priscilla Chan, and Alex Rives (BioHub’s head of science) trace the project from decade‑long philanthropic conversations to a focused initiative backed by $500 million. They describe an intentional strategy of tool‑building — funding long‑horizon methods and shared infrastructure across hubs in San Francisco, New York and Chicago — rather than narrow commercial product development. The team emphasized that many of the datasets they need do not yet exist, which motivates hands‑on wet‑lab work (imaging, cellular engineering, device development) to generate the observations required for scalable models.

A central technical milestone they discussed is ESM‑fold, an open protein language model released as a world model for protein biology. According to the team, ESM‑fold folded over 1.1 billion protein sequences, delivers atomic‑resolution structure predictions quickly, and performs especially well on protein–protein and antibody interaction tasks. They reported moving from in silico design to experimental validation: hundreds of thousands of digital trajectories were narrowed to 96 synthesized candidates, and the lab observed nanomolar binders for therapeutically relevant targets with structural confirmation by cryo‑EM and functional PD‑L cell assays. Alex and Mark argued that mechanistic interpretability of these models can reveal internal representations that map onto biochemical mechanisms, enabling hypothesis generation and—eventually—design of proteins that change physiology.

The guests were unanimous that open‑sourcing models and tools will accelerate scientific progress, broaden participation (including rare disease communities), and reduce centralization of power in a few institutions, though they acknowledged biosafety and regulatory complexities. They outlined priority areas such as inflammation and the immune system as testbeds for laddering from molecular to cellular to systemic models, and they framed their mission as mechanistic: understand the gene→protein→disease chain to enable personalized interventions. While they declined specific clinical predictions, they said the combination of expansive data generation, faster in‑silico design cycles, and tighter AI–lab feedback loops could compress timelines for discovery and change how clinical translation, recruitment, and regulation are approached over the coming decade.